Highlight
This large registry-based trial compared default treatment strategies with prasugrel versus ticagrelor in adult patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). No statistically significant difference was found in the primary composite endpoint of death, myocardial infarction (MI), or stroke at 1 year, though prasugrel had a slightly lower risk of major bleeding events.
The trial design—stepped-wedge, cluster-randomized, registry-based—reflected real-world clinical practice across multiple Swedish regions, enhancing generalizability to unselected ACS patients.
Specialty calculators
For clinical reference; use professional judgment.
